![]() ![]() "This data could be in anyone's hands now," said Comparitech's Paul Bischoff. "So, your ID and your medical card are probably somewhere on the dark web." Based on the data seen by researchers, affected persons are mostly from Utah, Nevada, and Colorado. Researchers found that the data of around 52,000 customers may have been impacted in the security incident. Sensitive customer data stored in a publicly accessible database included scans of passports, health insurance ID cards, and driver's licenses. The breach at Premier Diagnostics was discovered on February 22 by cybersecurity expert Bob Diachenko at consumer privacy watchdog Comparitech. (formerly known as Miraca Holdings Inc.) is a listed company on the Tokyo Stock Exchange – TYO: 4544.A Utah company has exposed the sensitive information of more than 50,000 customers by storing data on an unsecured server. For more information about Fujirebio Diagnostics, please call +1 61 or visit us at. Fujirebio Diagnostics specializes in the contract development and manufacturing for the diagnostics industry leaders and market development of novel in-vitro diagnostic products for the management of human disease states. and Fujirebio Holdings, Inc., is a premier diagnostics company and the industry leader in cancer biomarker tests. The company continues to expand its partnerships to accelerate best-in-class treatment options and further advancements in the field of medicine.įujirebio Diagnostics, Inc., a wholly owned subsidiary of H.U. ![]() The company focuses on the development of novel therapies for neurodegenerative diseases including Alzheimer’s disease. is a biopharmaceutical company based in South Korea with offices in the United States. The details of the clinical trial are available at .ĪriBio Co., Ltd. The study aims to assess the efficacy and safety of AR1001 in slowing the progression of Alzheimer's disease through various cognitive and functional assessments. We continue to partner with organizations and clinical experts across the world to develop new pathways for earlier, easier, and more complete neurodegenerative diagnostic tools,” stated Monte Wiltse, President and CEO of Fujirebio Diagnostics, Inc.ĪR1001-ADP3-US01 (NCT05531526) is Phase 3 Double-blind, Randomized, Placebo-controlled, Multi-center Trial to Evaluate the Efficacy and Safety of AR1001 over 52 Weeks in Participants with Early Alzheimer’s Disease. “Fujirebio continues to lead the industry in the development of high quality, functional tests to improve clinicians’ ability to detect and diagnose a variety of neurodegenerative conditions. We look forward to working closely with Fujirebio to improve the detection of Alzheimer’s disease and other neurodegenerative diseases with their pioneering assays,” commented James Rock, President of AriBio Co., Ltd US Office. Fujirebio is an ideal partner for us and reflects our commitment to advancements in this space. This initial partnership with Fujirebio is the first of several we plan to launch in the next few years as we expand our clinical programs into other areas of neurodegeneration. “AriBio is committed to advancing not just the treatment options for patients with Alzheimer’s disease and their families, but also the development of better diagnostics and improved characterization of this devastating disease. Fujirebio continues to make advances in the field to provide fully automated blood-based tests for Alzheimer’s disease and other neurological disorders. ![]() Fujirebio was the first company to develop and market cerebrospinal fluid (CSF) biomarkers for Alzheimer’s disease testing and the first to receive FDA authorization in 2022 for its Lumipulse® G β-Amyloid Ratio (1-42/ 1-40) test. The Phase 3 study in patients with early Alzheimer’s disease, AR1001-ADP3-US01, has been launched in the United States and plans to expand to other countries in 2023.įujirebio, a trusted partner for high-quality IVD testing solutions and a pioneer in neurodegenerative disease diagnostics is committed to the advancement of biomarkers to improve diagnosis of Alzheimer’s disease. ![]() AriBio completed a Phase 2 study in 2021 in mild to moderate Alzheimer’s disease patients with their lead compound AR1001, a PDE5 inhibitor with preclinical efficacy shown to inhibit neuron apoptosis, promote neurogenesis, increase neuroplasticity, and stimulate autophagy activity to remove toxic proteins. ![]()
0 Comments
Leave a Reply. |